ABVC BioPharma

CEO Dr. Uttam Patil also serves as interim CFO. The 10‑K reports material weaknesses with disclosure controls judged ineffective. The board includes several related individuals, and the organization relies on multiple related‑party transactions and subsidiaries, adding governance complexity.

While management has assembled collaborations, execution credibility is undermined by restatements and the decision to return certain licensing funds.